List of Excipients in Branded Drug CLONIDINE TRANSDERMAL SYSTEM USP, 0.1 MG/DAY

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
TruPharma LLC	CLONIDINE TRANSDERMAL SYSTEM USP, 0.1 MG/DAY	clonidine transdermal system	52817-505	LIGHT MINERAL OIL
TruPharma LLC	CLONIDINE TRANSDERMAL SYSTEM USP, 0.1 MG/DAY	clonidine transdermal system	52817-505	POLYISOBUTYLENE
TruPharma LLC	CLONIDINE TRANSDERMAL SYSTEM USP, 0.1 MG/DAY	clonidine transdermal system	52817-505	SILICON DIOXIDE
TruPharma LLC	CLONIDINE TRANSDERMAL SYSTEM USP, 0.1 MG/DAY	clonidine transdermal system	52817-610	MINERAL OIL

Clonidine Transdermal System USP 0.1 mg/day: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 24, 2026

Clonidine transdermal system USP, 0.1 mg/day, is a mature generic patch opportunity with limited regulatory exclusivity but meaningful technical barriers. The commercial value is concentrated in adhesive performance, dose-rate consistency, patch adhesion, packaging stability, and reliable supply of drug-in-adhesive or reservoir components. Clonidine is not a biologic, so biosimilar pathways do not apply. The principal competitive risks are low-price generic entry, authorized or branded-generic competition, and manufacturing failures involving crystallization, adhesion, or dose delivery.

What is clonidine transdermal system 0.1 mg/day?

Clonidine transdermal system 0.1 mg/day is a once-weekly delivery system that provides a nominal systemic delivery rate of 0.1 mg clonidine per day. The reference product is Catapres-TTS, originally marketed by Boehringer Ingelheim and approved by the FDA under NDA 019032. The product is used primarily for hypertension and is also associated clinically with off-label uses such as withdrawal symptoms, attention-deficit/hyperactivity disorder, and vasomotor symptoms.

The 0.1 mg/day strength is generally the entry strength in the product family. Commercial systems have also been marketed in 0.2 mg/day and 0.3 mg/day strengths.

Product attribute	Commercial significance
Active ingredient	Clonidine hydrochloride
Delivery rate	0.1 mg clonidine per day
Dosage form	Transdermal patch
Administration interval	Weekly
Reference product	Catapres-TTS
FDA application	NDA 019032
Generic pathway	ANDA, subject to FDA requirements
Biosimilar pathway	Not applicable
Primary technical risks	Adhesion, release rate, crystallization, residual drug, skin irritation
Primary commercial risks	Price erosion, limited market growth, manufacturing complexity

The product’s value is based on controlled transdermal delivery rather than on a novel active pharmaceutical ingredient. That shifts intellectual-property and differentiation priorities toward formulation, device construction, process control, and quality systems.

What excipients are used in clonidine transdermal systems?

The principal excipient strategy uses pressure-sensitive adhesive polymers, a mineral or silicon-based absorbent system, a membrane or rate-control layer, and multilayer backing and release materials. Exact composition varies by manufacturer and may be protected as confidential manufacturing information.

Public labeling for clonidine transdermal systems identifies inactive materials associated with the patch construction, including polyisobutylene and colloidal silicon dioxide. Polyester backing and fluoropolymer-coated release liners are also used in representative transdermal systems. The FDA label describes the product as a multilayer system with a backing layer, drug reservoir, rate-controlling membrane, adhesive layer, and release liner. [1]

Excipient function and formulation objective

Component	Typical material class	Function	Key development issue
Drug reservoir or adhesive matrix	Polyisobutylene-based polymer	Holds clonidine and controls migration	Drug solubility, crystallization, uniformity
Absorbent or rheology modifier	Colloidal silicon dioxide	Adjusts viscosity and stabilizes the matrix	Dispersion, batch-to-batch rheology
Pressure-sensitive adhesive	Polyisobutylene or related adhesive	Maintains skin contact	Peel, tack, shear, residue, irritation
Rate-control layer	Microporous polymer membrane	Limits drug flux	Pore structure and membrane uniformity
Backing layer	Polyester or other impermeable film	Protects the formulation and directs drug flow	Moisture barrier, flex resistance
Release liner	Fluoropolymer-coated film	Protects adhesive before application	Clean release and coating integrity
Perimeter or overlay adhesive	Acrylic or rubber-based system, depending on design	Improves wear time	Skin compatibility and edge lift

The preferred formulation depends on whether the product uses a reservoir architecture or a drug-in-adhesive architecture. A reservoir system can provide strong control of the delivery rate but requires more components and tighter assembly controls. A drug-in-adhesive system may reduce component count and manufacturing cost, but it increases the importance of drug dispersion, adhesive rheology, and crystal control.

How should an excipient strategy be designed for the 0.1 mg/day patch?

A successful excipient strategy should prioritize functional performance over nominal ingredient similarity. FDA approval of a generic transdermal system requires pharmaceutical equivalence and bioequivalence, but the sponsor must also demonstrate comparable product performance and address residual drug, adhesion, dose delivery, and skin interaction.

Polyisobutylene as the core adhesive platform

Polyisobutylene is commercially attractive because it has low water permeability, good chemical stability, and a long history in transdermal products. It can provide strong skin contact without relying on volatile solvents during use. Its limitations include limited compatibility with some drug loads, potential cold-flow behavior, and sensitivity to molecular-weight distribution.

Development priorities include:

• Clonidine hydrochloride solubility in the adhesive phase.
• Uniform drug distribution across the coated web.
• Control of adhesive modulus and peel force.
• Prevention of crystallization during accelerated stability.
• Low residue after patch removal.
• Consistent adhesion over seven days.

The excipient supplier should be qualified not only by compendial grade but also by polymer molecular-weight distribution, residual monomer profile, viscosity, and lot-to-lot adhesive behavior.

Colloidal silicon dioxide as a rheology and stabilization tool

Colloidal silicon dioxide can increase viscosity, improve suspension behavior, and reduce sedimentation or migration in a reservoir or matrix system. Excessive loading can reduce coating uniformity, increase haze, impair drug diffusion, or weaken adhesion.

A commercial formulation program should therefore optimize silicon dioxide by surface treatment, particle-size distribution, and concentration. The key opportunity is not simply replacing one silicon dioxide grade with another. It is developing a validated grade and dispersion process that delivers stable rheology without reducing clonidine flux.

Membrane and liner selection

The rate-controlling membrane and release liner can create meaningful supplier and manufacturing advantages. A membrane with controlled porosity can reduce variability in drug delivery, while a release liner with consistent silicone or fluoropolymer coating can reduce patch damage during die cutting and application.

Potential commercial opportunities include:

• Dual-source qualification for specialty membranes.
• Custom release liners with lower delamination force.
• Pre-coated adhesive webs for contract manufacturing.
• Improved backing films with better moisture protection.
• Lower-waste roll stock designed for high-speed converting.

These components can become supply bottlenecks because they are less interchangeable than conventional tablet excipients.

What FDA regulatory requirements apply to clonidine patches?

Clonidine transdermal systems are regulated as drug-device combination products, with the drug constituent as the primary mode of action. An ANDA applicant must establish equivalence to the reference listed drug and comply with applicable FDA requirements for transdermal systems.

Relevant evidence typically includes:

1. Pharmaceutical equivalence in strength, dosage form, route, and active ingredient.
2. Comparative in vitro release testing.
3. Adhesion testing under the applicable FDA framework.
4. In vivo pharmacokinetic bioequivalence.
5. Residual drug characterization.
6. Extractables and leachables assessment.
7. Container-closure and pouch integrity testing.
8. Skin irritation and sensitization evaluation where required.
9. Stability data covering the proposed shelf life.
10. Manufacturing controls for coating, lamination, die cutting, and packaging.

The FDA has issued product-specific guidances for certain transdermal and topical products and has published broader guidance covering adhesion studies for transdermal and topical delivery systems. [2] [3] A sponsor should expect the FDA to focus on adhesion because patch detachment can reduce exposure and create safety or efficacy variability.

What is the Orange Book status of clonidine transdermal system?

The reference product is an FDA-approved prescription drug, and generic applicants generally use the ANDA pathway rather than a 505(b)(2) application when they can demonstrate equivalence to the reference product.

The key Orange Book issues are:

Issue	Assessment
Reference listed drug	Catapres-TTS
Regulatory application	NDA 019032
Generic pathway	ANDA
Drug type	Small molecule
Biosimilar designation	Not applicable
Likely current regulatory barrier	Equivalence and manufacturing performance
Commercial exclusivity	Mature product; no expected new-molecule exclusivity
Orange Book patent risk	Primarily dependent on any currently listed, unexpired patents and regulatory exclusivity

Because Catapres-TTS was approved decades ago, original composition, formulation, and delivery-system patents are expected to be expired. Current commercial risk should be assessed against the FDA’s live Orange Book patent and exclusivity listings rather than historical patent documents. [4]

When does clonidine transdermal system lose exclusivity?

Clonidine transdermal system has already passed the principal exclusivity period associated with the original approval. The relevant commercial question is not loss of new-drug exclusivity but the remaining strength of any enforceable formulation, device, method-of-use, or manufacturing patents.

Patent categories relevant to the product

Patent category	Relevance to a 0.1 mg/day patch	Expected status for an older product
Clonidine compound patents	Protect the active ingredient	Expired
Original transdermal system patents	Protect reservoir, membrane, or patch construction	Generally expired
Dose-rate patents	Protect 0.1, 0.2, or 0.3 mg/day delivery	Likely expired or weak
Adhesive formulation patents	Protect specific polymer and additive combinations	May exist only for later improvements
Method-of-use patents	Protect hypertension or other indications	Limited value if expired or carved out
Manufacturing patents	Protect coating, assembly, or packaging processes	Potentially relevant if later-filed
Design patents	Protect patch appearance or physical design	Limited regulatory value

For an ANDA sponsor, the legal work should focus on any unexpired Orange Book-listed patents, non-Orange Book patents that may support litigation, and the risk that a novel formulation could trigger a 505(b)(2) strategy rather than a standard ANDA.

What Paragraph IV challenges and litigation affect clonidine patches?

A Paragraph IV certification would be relevant only if an unexpired patent were listed for the reference product. A generic sponsor could certify that the patent is invalid, unenforceable, or not infringed. If the patent owner brought suit within the statutory period, the FDA approval could be subject to a 30-month stay under the applicable Hatch-Waxman framework. [5]

For this mature clonidine patch product, the principal litigation risk is likely to arise from a later patent covering:

• A specific drug-in-adhesive composition.
• A membrane architecture.
• A low-irritation adhesive system.
• A manufacturing process that improves content uniformity.
• A formulation that reduces clonidine crystallization.
• A packaging configuration that extends shelf life.

Method-of-use patents may have limited blocking power if the generic label uses approved indications and omits patented uses where permitted. A formulation or device patent is more commercially relevant because it can directly constrain the generic product design.

What formulation patents could protect a new clonidine patch?

A new patent estate would need to claim a measurable technical advantage, not merely the use of clonidine in a conventional patch. Potentially defensible claim themes include:

Low-crystallization adhesive matrices

Claims could focus on a defined clonidine concentration, polymer molecular-weight range, silicon dioxide level, and absence of visible crystals after accelerated storage. The strongest position would link the composition to improved flux consistency and shelf life.

High-adhesion, low-irritation systems

A formulation that maintains seven-day adhesion while reducing erythema, pruritus, or adhesive residue could support a differentiated product. Clinical and comparative adhesion data would strengthen commercial value.

Abuse-deterrent or tamper-resistant delivery

A patch designed to limit drug extraction, cutting, or dose dumping could target institutional, pediatric, or controlled-use markets. Commercial viability would depend on the clinical need and whether the added structure increases cost or skin burden.

Pediatric or low-dose systems

A smaller patch with a lower delivery rate could create a product opportunity for pediatric or geriatric use. Such a product would likely require a distinct regulatory strategy and clinical justification.

How strong is the patent estate for clonidine transdermal system?

The legacy patent estate is likely weak as a barrier to conventional generic entry because the active ingredient and original transdermal platform are old. The stronger protection is operational rather than legal.

Protection type	Relative strength
Original clonidine molecule patents	None expected from an exclusivity standpoint
Original Catapres-TTS architecture	Low, given product age
New adhesive formulation	Moderate if technically narrow but clinically meaningful
Manufacturing know-how	Moderate to strong as a practical barrier
Supplier qualification and process capability	Strong operational value
Brand recognition	Moderate in hypertension and chronic-use channels
Regulatory file and reference-product data	Important for generic development

A competitor can often design around a narrow adhesive or membrane patent. It is harder to reproduce a validated coating process, consistent seven-day adhesion profile, stable residual-drug profile, and robust supply chain at a competitive cost.

What commercial opportunities exist for clonidine transdermal system?

The most credible opportunities are generic supply, private-label manufacturing, formulation improvement, and excipient or component supply.

Generic and authorized-generic supply

A sponsor can compete through:

• ANDA approval for 0.1 mg/day.
• A complete strength portfolio covering 0.1, 0.2, and 0.3 mg/day.
• Reliable hospital and group-purchasing supply.
• Private-label distribution.
• Dual sourcing of critical membranes, liners, and adhesive polymers.

The market is mature, so volume and supply reliability are likely to matter more than premium pricing.

Reformulated transdermal products

A differentiated patch could target patients with poor adherence to oral clonidine or difficulty swallowing tablets. Product concepts include lower-irritation adhesives, smaller patch footprints, reduced residue, improved water resistance, and easier application.

A reformulated product may require a 505(b)(2) application if it cannot rely fully on ANDA equivalence. The higher regulatory cost could be justified only by a clear clinical or commercial advantage.

Excipient and component supply

Specialty suppliers can pursue:

• Pharmaceutical-grade polyisobutylene with controlled rheology.
• Pre-dispersed colloidal silicon dioxide concentrates.
• Low-extractables release liners.
• High-barrier polyester backing films.
• Custom microporous membranes.
• Contract coating and converting.
• Stability-indicating analytical methods for clonidine patches.

Component suppliers with validated transdermal histories may have stronger pricing power than commodity excipient vendors.

Contract development and manufacturing

CDMOs with solvent coating, hot-melt coating, web handling, lamination, die cutting, pouching, and vision inspection capabilities can offer an integrated service. The most valuable capabilities are low-loss coating, accurate dose uniformity, clean die cutting, and packaging integrity.

What generic launch scenarios exist for clonidine 0.1 mg/day?

Scenario	Timing profile	Commercial impact
Conventional ANDA launch	After approval and resolution of any listed patent issues	Rapid price competition
Authorized-generic launch	Controlled by reference-product owner or licensee	Limits independent generic pricing
Multi-strength launch	0.1 mg/day introduced with 0.2 and 0.3 mg/day	Improves portfolio economics
Differentiated 505(b)(2) patch	Requires additional development and regulatory work	Higher margin potential, higher cost
Supply-constrained market entry	Launch during competitor shortage	Temporary pricing advantage
Private-label partnership	Manufacturer supplies approved product to distributors	Lower commercial overhead

The 0.1 mg/day strength is likely to face the greatest price pressure because it is the standard entry dose and the most logical first generic strength.

How does clonidine transdermal system compare with oral clonidine?

Attribute	Transdermal clonidine	Oral clonidine
Dosing frequency	Weekly	Usually multiple daily doses
Adherence	Potentially improved	More dependent on daily compliance
Onset and offset	Slower	Faster
Manufacturing complexity	High	Lower
Formulation differentiation	Meaningful	More limited
Patch-specific risks	Adhesion, skin reaction, dose variability	Swallowing and peak-trough exposure
Generic barrier	Transdermal equivalence	Conventional oral equivalence
Commercial opportunity	Device and formulation improvement	Cost and supply efficiency

The patch can command a strategic role where adherence, stable exposure, or reduced daily dosing is important. Its production cost and regulatory burden are higher than those of tablets.

What geographic coverage and manufacturing barriers matter?

The United States is governed by FDA ANDA and Orange Book requirements. European Union products are regulated under national or centralized procedures depending on the application strategy, with transdermal equivalence and quality requirements assessed by the relevant authority. Other markets may accept abridged applications but still require local stability, packaging, and pharmacopoeial compliance.

The main geographic barriers are:

• Different expectations for transdermal bioequivalence.
• Local requirements for adhesive and skin-tolerance data.
• Country-specific labeling and indication carve-outs.
• Transport sensitivity to temperature and humidity.
• Limited availability of qualified membrane and liner suppliers.
• Site-transfer risk for coating and converting operations.

Manufacturing transfer is particularly sensitive. Changes in polymer grade, coating head, drying profile, web speed, membrane supplier, or pouch seal can alter clonidine delivery. Comparability protocols should be established before commercial scale-up.

Key Takeaways

• Clonidine transdermal system USP 0.1 mg/day is a mature generic and combination-product opportunity.
• The principal formulation platform uses polyisobutylene-based adhesive materials, colloidal silicon dioxide, a rate-control membrane, backing film, and release liner.
• Original molecule and early transdermal patents are expected to provide little current exclusivity protection.
• Current legal risk depends on live Orange Book listings, later formulation patents, and non-Orange Book device or manufacturing claims.
• The strongest practical barriers are coating uniformity, seven-day adhesion, crystallization control, packaging integrity, and qualified component supply.
• The best commercial opportunities are reliable ANDA supply, private-label manufacturing, specialty excipient supply, CDMO services, and differentiated low-irritation or pediatric systems.
• Biosimilar competition is irrelevant because clonidine is a small-molecule drug.
• A premium reformulated product would likely require a 505(b)(2) strategy and a demonstrable patient or adherence advantage.

FAQs About Clonidine Transdermal System 0.1 mg/day

Is clonidine transdermal system 0.1 mg/day a combination product?

Yes. It is regulated as a drug-device combination product because clonidine provides the pharmacologic action while the patch controls delivery and maintains skin contact.

Can a manufacturer replace polyisobutylene with an acrylic adhesive?

Yes, but the replacement may affect drug release, skin adhesion, irritation, residual drug, and bioequivalence. The change would require comparative development and regulatory justification.

Is clonidine patch manufacturing difficult compared with tablet manufacturing?

Yes. Transdermal manufacturing requires precision coating, lamination, die cutting, web inspection, pouching, and control of adhesive and membrane properties. Small process changes can affect delivery rate.

Can a generic clonidine patch use a different patch size?

A different size may be possible if the product demonstrates equivalent delivery, adhesion, dose uniformity, and performance. A size change can alter flux, wear characteristics, and patient handling.

Does clonidine transdermal system have biosimilar risk?

No. Biosimilars apply to biological products. Clonidine is a chemically synthesized small molecule and is subject to generic drug pathways.

References

1. U.S. Food and Drug Administration. (n.d.). Catapres-TTS clonidine transdermal system prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2019). Assessing adhesion with transdermal and topical delivery systems for ANDAs: Guidance for industry.
3. U.S. Food and Drug Administration. (2023). Product-specific guidance for clonidine hydrochloride transdermal system.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).